People who have difficulty building immunity from COVID-19 vaccines now have a new medication to turn to for help.
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization for Pemgarda, a preventative medication designed for immunocompromised individuals. The EUA was granted to Invivyd, a drug manufacturer based in Massachusetts.
What is Pemgarda?
Pemgarda, whose main ingredient is pemivibart, is a long-acting monoclonal antibody authorized for people aged 12 years and older with moderate-to-severe immune compromise resulting from a medical condition or immunosuppressant medications.
A.C. Dahnke
Author
A.C. Dahnke is a freelance writer and editor residing in California. She has covered community journalism and health care news for nearly a decade, winning a California Newspaper Publishers Award for her work.
